Nitrite Reductase Detection for Tuberculosis Severity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis treatment methods fail to effectively detect dormant Mycobacterium tuberculosis bacilli and assess their conversion to active forms, leading to drug resistance and prolonged treatment periods, as well as the inability to accurately diagnose latent infections and monitor treatment efficacy.
Innovation Solution
A method involving the use of sulphanilic acid and N-(1-napthyl) ethylenediamine dihydrochloride to detect nitrite levels in sputum samples, which correlates with the severity of tuberculosis and identifies nitrite reductase as a potential drug target for dormant stages of Mycobacterium tuberculosis, utilizing the nitrate metabolic pathway enzymes to develop anti-tubercular drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple antibiotics are administered over a long period to treat TB, then treatment efficacy is improved, but drug resistance develops and treatment complexity increases
Solution Approach 1:
The patent extracts and targets the specific metabolic pathway (nitrate reduction pathway) that is essential for dormant bacilli survival. By focusing on nitrite reductase enzyme and its role in converting nitrate to nitrite, the treatment can specifically target dormant bacilli without requiring complex multi-drug regimens, thereby simplifying treatment while maintaining efficacy.
Solution Approach 2:
The patent changes the treatment parameter from targeting general bacterial growth to targeting specific metabolic activity (nitrate reduction) that occurs during dormancy. This parameter change allows for more precise and effective treatment of latent TB infections, reducing the need for prolonged multi-drug therapy.
2Measurement precision
If traditional diagnostic methods are used to detect TB, then active infections can be identified, but dormant/latent infections cannot be detected
Solution Approach 1:
The patent introduces nitrite as an intermediary marker that connects dormant bacilli metabolism to detectable signals. By measuring nitrite levels produced through the nitrate reduction pathway, the diagnostic method can detect dormant infections that traditional methods miss, expanding the detection range while maintaining precision.
Solution Approach 2:
The patent replaces mechanical/direct detection methods (microscopy, culture) with a biochemical detection system that measures metabolic byproducts (nitrite). This substitution enables detection of dormant bacilli that are metabolically active but not replicating, thereby expanding detection capabilities without compromising accuracy.
3Reliability
If nitrate reduction pathway enzymes are targeted, then dormant bacilli can be effectively treated, but the complexity of drug development increases
Solution Approach 1:
The patent segments the complex problem of TB treatment by focusing on a specific metabolic pathway (nitrate reduction) rather than attempting to target all bacterial functions. This segmentation allows for more focused drug development against nitrite reductase, reducing overall development complexity while maintaining high efficacy against dormant bacilli.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, cost-effective detection of tuberculosis severity and identification of nitrite reductase as a drug target, enabling effective targeting of dormant bacilli and improving treatment monitoring, thereby addressing the limitations of existing diagnostic and therapeutic methods.
Implementation Method 1
nitrate reductase (NarGHJI) played an important role during transition from the aerobic to anaerobic dormant stage
Implementation Method 2
nitrite reductase (NirBD), which converts nitrite to ammonia
Implementation Method 3
adding reagents sulphanilic acid and N-(1-napthyl) ethylenediamine dihydrochloride to a sputum sample obtained from a subject; and detecting color intensity of the solution obtained
Data Source
Figure 1a~1b
Figure 2~3
Figure 4~5
AI summary
The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.